Cosentyx snrdy 300MG dose-2PENML
Ended Awarded Last action
- Contract number
- SPE2DR26FZ0Q1
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $23,488
Award facts
- Contract value 100% obligated
- $23,487.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $23,487.50 by the Defense Logistics Agency on January 6, 2026, for the supply of Cosentyx (secukinumab) 300mg dose in 2-pen packages. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open procurement. The ultimate completion date is set for January 7, 2026, with performance to occur at the awardee's Conshohocken facility. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026), which serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical commodities to support military healthcare programs worldwide.
The Defense Logistics Agency's Medical Supply Chain relies on AmerisourceBergen and its parent company Cencora, Inc. to deliver critical pharmaceuticals across multiple therapeutic domains to support Defense Health Agency operations, U.S. Coast Guard healthcare needs, and other federal medical institutions. Cosentyx, a biologic immunosuppressant used to treat inflammatory conditions such as psoriasis and rheumatoid arthritis, represents the specialized medical commodities routinely procured through this contracting vehicle to support military treatment facilities and veteran healthcare programs. The company's extensive federal procurement history demonstrates its capability to efficiently fulfill government requirements for essential pharmaceutical supplies through competitive, firm fixed-price contracting mechanisms.
Quick answers
Who was awarded contract SPE2DR26FZ0Q1?
SPE2DR26FZ0Q1 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 6, 2026.
How much is contract SPE2DR26FZ0Q1 worth?
The government has obligated $23,488 on SPE2DR26FZ0Q1.
Is contract SPE2DR26FZ0Q1 an order under another contract?
Yes. SPE2DR26FZ0Q1 is a delivery order under SPE2DR25D2018, an indefinite delivery contract.
Was contract SPE2DR26FZ0Q1 competed?
The extent of competition for SPE2DR26FZ0Q1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award